01 AI-driven Multiomics Integration Enhancing Precision Oncology The lung cancer genomic testing market is witnessing a transition from single-gene assays to AI-enabled multi-omics platforms that integrate genomic, transcriptomic, and clinical data for comprehensive treatment selection. This shift is improving the identification of actionable biomarkers, supporting personalized therapies, and enhancing clinical decision-making. Healthcare providers are increasingly adopting these advanced analytical platforms to improve diagnostic confidence and patient outcomes. For example, Tempus AI combines artificial intelligence with molecular and clinical datasets to support precision oncology workflows.
02 Expansion of Liquid Biopsy-Based Genomic Testing The market is experiencing growing adoption of liquid biopsy technologies as healthcare providers increasingly prefer minimally invasive genomic testing for lung cancer diagnosis and treatment monitoring. This transition is enabling faster detection of actionable mutations, facilitating repeat testing, and improving access to precision medicine for patients who cannot undergo tissue biopsy. As a result, liquid biopsy is becoming an important complement to conventional tissue-based testing across oncology practices. For example, Guardant Health offers liquid biopsy genomic tests that identify clinically relevant mutations in patients with advanced lung cancer.
01 The lung cancer genomic testing market is sensitive to disruptions due to its dependence on advanced sequencing instruments, specialized reagents, laboratory consumables, and globally sourced diagnostic components. Supply chain disruptions have affected the timely availability of testing kits, sequencing platforms, and logistics for sample transportation, resulting in delayed diagnostic workflows and reduced laboratory efficiency across multiple regions. The market is experiencing a capacity-constrained recovery, supported by supplier diversification, localized manufacturing, strategic inventory management, and investments in resilient diagnostic supply networks.
01 The lung cancer genomic testing market forecasts sustained investment activity due to increasing adoption of precision oncology, rising demand for liquid biopsy and companion diagnostics, and expanding integration of AI-driven genomic analysis into clinical workflows.In 2025, Caris Life Sciences completed its Nasdaq initial public offering, raising approximately USD 423.5 million to accelerate the expansion of its precision oncology business. The capital is being utilized to strengthen commercialization of its comprehensive molecular profiling and genomic testing portfolio, expand laboratory and bioinformatics capabilities, advance companion diagnostic development, and support research across multiple cancer types.
01 Increasing Adoption of Precision Oncology and Advancements in Next-Generation Sequencing Drive the Market The growing adoption of precision oncology is driving demand for lung cancer genomic testing by enabling clinicians to identify actionable genetic mutations and match patients with targeted therapies. Healthcare systems are increasingly incorporating biomarker testing into standard treatment pathways to improve clinical outcomes and reduce ineffective treatments. The expanding availability of targeted drugs for mutations such as EGFR, ALK, ROS1, KRAS, and BRAF further increases the need for comprehensive genomic profiling before treatment initiation.Continuous advancements in next-generation sequencing technologies are increasing the speed, scalability, and analytical performance, thereby strengthening market demand. New sequencing platforms are enabling laboratories to process larger sample volumes with shorter turnaround times while maintaining high sequencing accuracy, making comprehensive genomic profiling more accessible. These innovations are helping healthcare providers improve workflow efficiency and support faster treatment decisions for patients with non-small cell lung cancer.
01 High Cost of Comprehensive Genomic Testing and Limited Access to Standardized Biomarker Testing Restrain Market Expansion Comprehensive genomic testing requires advanced next-generation sequencing instruments, specialized bioinformatics platforms, and highly trained personnel, resulting in significant capital and operational costs. Smaller hospitals and diagnostic laboratories, particularly in developing regions, often face budget constraints that limit the adoption of advanced genomic testing services.Differences in reimbursement policies and uneven access to standardized biomarker testing limit the routine implementation of lung cancer genomic testing across healthcare systems. Many healthcare providers face challenges in recovering the costs associated with comprehensive genomic profiling, while limited testing infrastructure delays access to precision oncology services.
01 Expansion of Comprehensive Genomic Profiling and Decentralization of Next-generation Sequencing Offer Growth Opportunities to Market Players The increasing use of comprehensive genomic profiling in early-stage lung cancer creates significant growth opportunities for genomic testing companies, sequencing platform manufacturers, and diagnostic laboratories. Earlier molecular characterization enables clinicians to identify patients who may benefit from targeted therapies and clinical trials before disease progression. As treatment guidelines continue to expand biomarker testing across earlier stages of lung cancer, demand for advanced genomic assays is expected to grow.The expansion of national oncology networks is creating significant opportunities for genomic testing laboratories, bioinformatics providers, and companion diagnostic developers. Governments and healthcare systems are increasingly integrating comprehensive genomic profiling into nationwide cancer care pathways, increasing testing volumes and improving access to precision medicine. This transition is expected to generate long-term demand for standardized genomic testing services, data interpretation platforms, and molecular diagnostics.
01 Complex Interpretation of Genomic Variants and Fragmented Companion Diagnostic Approvals Challenge Market Growth A major challenge for the lung cancer genomic testing market is the interpretation of complex genomic variants and the continuous emergence of new clinically relevant biomarkers. Laboratories must frequently update bioinformatics pipelines, variant databases, and reporting standards to align with evolving scientific evidence and treatment guidelines. This increases reporting complexity, delays clinical decision-making, and creates variability in test interpretation, limiting the scalability of precision oncology services.The co-development of companion diagnostics and targeted therapies often results in different regulatory approvals, testing requirements, and biomarker eligibility criteria across regions. This creates complexity for clinical laboratories and healthcare providers in selecting the appropriate test for each therapy, slowing the adoption of standardized genomic testing workflows. For example, different targeted therapies for EGFR, ALK, and MET alterations may have therapy-specific companion diagnostic requirements, increasing operational complexity for oncology laboratories.
June 2026 Guardant Health received US FDA approval for Guardant360 CDx as the companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib) to identify patients with HER2-mutant advanced non-small cell lung cancer (NSCLC) eligible for targeted therapy.
May 2026 Tempus AI received US FDA approval for the tumor-only indication of its xT CDx comprehensive genomic profiling assay, making it the first laboratory with FDA-approved companion diagnostic indications for both tumor-only and tumor-normal comprehensive genomic profiling.
March 2026 Illumina and Labcorp expanded their strategic collaboration to improve access to next-generation sequencing (NGS)-based precision oncology testing, including distributed biomarker testing, evidence generation for payer coverage, and development of new genomic assays.
September 2025 Illumina announced new partnerships with multiple global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology Comprehensive genomic profiling test, with an initial focus on KRAS biomarkers for precision oncology.